Apremilast was the first PDE4 inhibitor and is currently US Food and Drug Administration (FDA) and European Medicines Agency (EMA)-approved for psoriasis, psoriatic arthritis, and oral ulcers of Behcet’s disease [9]. This evidence concerns the gene PDE4A and Oral ulcer.